医学
腋窝
哨兵节点
乳腺癌
活检
腋窝解剖
腋窝淋巴结清扫术
外科
前哨淋巴结
回顾性队列研究
队列
新辅助治疗
癌症
内科学
作者
Sabrina Kahler Ribeiro Fontana,Eleonora Pagan,Francesca Magnoni,Elisa Vicini,Consuelo Morigi,Giovanni Corso,Mattia Intra,Fiorella Canegallo,Silvia Ratini,Maria Cristina Leonardi,Eliana La Rocca,Vincenzo Bagnardi,Emilia Montagna,Marco Colleoni,Giuseppe Viale,Luca Bottiglieri,Chiara Maria Grana,Jorge Villanova Biasuz,Giulia Veronesi,Viviana Galimberti
出处
期刊:Ejso
[Elsevier]
日期:2021-04-01
卷期号:47 (4): 804-812
被引量:102
标识
DOI:10.1016/j.ejso.2020.10.014
摘要
Introduction In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment (NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel node biopsy (SNB) is still debatable, since the false-negative rate (FNR) is significantly high (12.6–14.2%). The objective of this retrospective mono-institutional study, with a long follow-up, aimed to evaluate the outcome in patients undergoing NAT who remained or converted to cN0 and received SNB independent of target axillary dissection (TAD) or the removal of at least 3 sentinel nodes (SNs). Methods This study analyzed 688 consecutive cT1-3, cN0/1/2 patients, operated at the European Institute of Oncology, Milan, from 2000 to 2015 who became or remained cN0 after NAT and underwent SNB with a least one SN found. Axillary dissection (AD) was not performed if the SN was negative. Nodal radiotherapy (RT) was not mandatory. Results Axillary failure occurred in 1.8% of the initially cN1/2 patients and in 1.5% of the initially cN0 patients. After a median follow-up of 9.2 years (IQR 5.3–12.3), the 5- and 10-year overall survival (OS) were 91.3% (95% CI, 88.8–93.2) and 81.0% (95% CI, 77.2–84.2) in the whole cohort, 92.0% (95% CI, 89.0–94.2) and 81.5% (95% CI, 76.9–85.2) in those initially cN0, 89.8% (95% CI, 85.0–93.2) and 80.1% (95% CI, 72.8–85.7) in those initially cN1/2. Conclusion The 10-year follow-up confirmed our preliminary data that the use of standard SNB is acceptable in cN1/2 patients who become cN0 after NAT and will not translate into a worse outcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI